Sanofi Takes $10.88 Million Position in AnaptysBio, Inc. (NASDAQ:ANAB)

Sanofi acquired a new stake in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 821,917 shares of the biotechnology company's stock, valued at approximately $10,882,000. AnaptysBio comprises 6.2% of Sanofi's investment portfolio, making the stock its 4th largest holding. Sanofi owned 2.70% of AnaptysBio at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of ANAB. Fairmount Funds Management LLC bought a new stake in shares of AnaptysBio during the 4th quarter worth about $24,050,000. Boxer Capital Management LLC acquired a new stake in AnaptysBio in the 4th quarter worth approximately $17,212,000. Vanguard Group Inc. boosted its position in AnaptysBio by 8.4% during the fourth quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock worth $24,411,000 after purchasing an additional 143,584 shares during the period. Ensign Peak Advisors Inc boosted its position in AnaptysBio by 184.4% during the fourth quarter. Ensign Peak Advisors Inc now owns 215,454 shares of the biotechnology company's stock worth $2,853,000 after purchasing an additional 139,699 shares during the period. Finally, Granahan Investment Management LLC bought a new position in shares of AnaptysBio in the fourth quarter valued at approximately $1,404,000.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ANAB. Johnson Rice reaffirmed a "buy" rating on shares of AnaptysBio in a report on Wednesday, March 26th. Guggenheim upped their price target on shares of AnaptysBio from $52.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. Wells Fargo & Company raised their price target on AnaptysBio from $40.00 to $51.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. Wolfe Research assumed coverage on AnaptysBio in a research note on Tuesday, February 4th. They set an "outperform" rating and a $25.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their price target on AnaptysBio from $36.00 to $42.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, AnaptysBio currently has a consensus rating of "Moderate Buy" and a consensus price target of $35.88.

AnaptysBio Trading Down 0.4%

ANAB stock traded down $0.08 during trading on Thursday, hitting $20.73. 163,530 shares of the stock traded hands, compared to its average volume of 598,954. The stock has a market cap of $609.05 million, a price-to-earnings ratio of -3.40 and a beta of -0.20. AnaptysBio, Inc. has a one year low of $12.21 and a one year high of $41.31. The company has a 50 day simple moving average of $19.19 and a 200 day simple moving average of $18.27.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.30) by $0.02. The company had revenue of $27.77 million during the quarter, compared to analysts' expectations of $15.27 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. As a group, analysts predict that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio announced that its board has authorized a stock repurchase plan on Monday, March 24th that authorizes the company to repurchase $75.00 million in shares. This repurchase authorization authorizes the biotechnology company to reacquire up to 13.1% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's management believes its stock is undervalued.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.